Document Detail

Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses.
MedLine Citation:
PMID:  20964369     Owner:  NLM     Status:  In-Process    
Oncolytic adenoviruses are an emerging treatment option for advanced and refractory cancer. Such patients are often treated with corticosteroids to ameliorate tumor associated symptoms. Thus, it is important to evaluate whether safety is affected by immunosuppression possibly induced by corticosteroids. Concurrent low-dose cyclophosphamide, appealing for its immunomodulatory effects, could also impact safety. In a retrospective case-control study, we evaluated the effect of systemic corticosteroid use in cancer patients receiving oncolytic virotherapy. Four treatment groups were identified: (1) oncolytic adenovirus with oral glucocorticoids, (2) virus alone, (3) virus with glucocorticoids and cyclophosphamide and (4) virus with cyclophosphamide. Adverse events, neutralizing antibody titers, viral DNA in circulation and tumor responses were evaluated. The most common adverse effects were grade 1-2 fatigue, nausea, fever and abdominal pain. Common asymptomatic findings included self-limiting grade 1-3 hyponatremia and aspartate aminotransferase increase. Safety was good and no significant differences were observed between the groups. All patients had an increase in neutralizing antibody titers post-treatment, and no trends for differences between groups were observed. There were fewer post-treatment virus genomes circulating in patients receiving glucocorticoids when compared to their control groups. Overall, glucocorticoid use in cancer patients receiving oncolytic adenovirus, with or without low-dose cyclophosphamide, seems safe.
Maria Rajecki; Mari Raki; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Andreas Helminen; Päivi Hannuksela; Kaarina Partanen; Leena Laasonen; Timo Joensuu; Lotta Kangasniemi; Elina Haavisto; Anna Kanerva; Laura Ahtiainen; Akseli Hemminki
Related Documents :
8936659 - The effect of somatostatin versus corticosteroid in the treatment of graves' ophthalmop...
9016889 - Treatment of lupus nephritis: a meta-analysis of clinical trials.
8493629 - Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asth...
19240379 - Adherence with long-term asthma management in patients who experienced hospitalized ast...
8882069 - Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to...
11371659 - Intravenous immunoglobulin application following immunoadsorption: benefit or risk in p...
24020649 - Administration of isoproterenol and adenosine to guide supplemental ablation after pulm...
466329 - Comparative trial of volunteer and professional treatments of dysphasia after stroke.
13573189 - Mortality rates in patients with burns; a report of experience at san francisco city an...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-08
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  8     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  93-103     Citation Subset:  IM    
Cancer Gene Therapy Group, Transplantation Laboratory and Haartman Institute and Finnish Institute of Molecular Medicine, University of Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular insights on the cyclic peptide nanotube-mediated transportation of antitumor drug 5-fluoro...
Next Document:  ?-propeller phytase hydrolyzes insoluble Ca(2+)-phytate salts and completely abrogates the ability o...